Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast to 2022
“The global infectious disease diagnostics market is projected to grow at a CAGR of 5.6%.”
The global infectious disease diagnostics market is expected to reach USD 19.35 billion by 2022 from USD 14.73 billion in 2017, at a CAGR of 5.6%. Growth in this market can primarily be attributed to factors such as increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics. However, inadequate reimbursement and rising healthcare cost limiting usage of novel diagnostic technologies are expected to restrain the growth of this market during the forecast period.
“The assays, kits, & reagents segment accounted for the largest share in 2017.”
Based on product & service, the infectious disease diagnostics market is segmented into assays, kits, & reagents; instruments; and services & software. The assays, kits, and reagents segment accounted for the largest share of the global infectious disease diagnostics market in 2017. The large share of this segment can be attributed to the increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages.
“Asia Pacific is projected to grow at the highest CAGR during the forecast period.”
Geographically, Asia Pacific is expected to register the highest CAGR during the forecast period. The growth of this regional segment can be attributed to the growing GDPs and a significant rise in disposable income levels, increased healthcare spending by a larger population base, modernization of healthcare infrastructure, and rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas).
Break-up profile of primaries:
By Company Type- Tier 40%, Tier 30%, and Tier 30%
By Designation-C-level-27%, D-level-18%, and Others-55%
By Region-North America-50%, Europe-20%, Asia Pacific-20%, and RoW-10%
The key players in the global infectious disease diagnostics market are Abbott (US), Becton, Dickinson and Company (BD) (US), bioMerieux (France), Bio-Rad (US), and Roche (Switzerland).
The infectious disease diagnostics market in this report is segmented by product & service, disease type, technology, end user, and region. The study tracks and analyzes competitive developments such as product launches & approvals, acquisitions, collaborations, agreements, partnerships, and expansions, and profiles key players and core competencies in the infectious disease diagnostics market.
Reasons to buy this report:
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on portfolios offered by the top players in the global infectious disease diagnostics market. The report analyzes the market by product & service, disease type, technology, end user, and region
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global infectious disease diagnostics market
Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for infectious disease diagnostic products across regions
Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global infectious disease diagnostics market
Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global infectious disease diagnostics market